Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients… Continue reading →
Ibrutinib is active in previously treated Waldenstro¨m macroglobulinemia (WM). MYD88 mutations
(MYD88MUT) and CXCR4 mutations (CXCR4MUT) affect ibrutinib response. We report on a prospective
study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and the effect
of… Continue reading →
In the article that accompanies this editorial, Treon and colleagues
1 report on 30 newly diagnosed patients with Waldenstr¨om
macroglobulinemia (WM) treated with ibrutinib. Clinically relevant
responses were seen in all patients. Responses occurred rapidly
with an 18-month… Continue reading →
Ibrutinib monotherapy is a highly active and tolerable option for treatment-naïve patients with Waldenström macroglobulinemia (WM), but may be affected by CXCR4-mutation status, according to a study published in the Journal of Clinical Oncology… Continue reading →
Recently, Dr. John Chapin, a Professor of Communications at the Pennsylvania State University’s Beaver Campus approached the IWMF about a project whereby his students would develop and produce short videos for the IWMF.
Results from the phase III iNNOVATE (PCYC-1127) trial established the combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) as the new standard of care in Waldenström macroglobulinemia, said Meletios A. Dimopoulos, MD.
A type of non-Hodgkin lymphoma, Waldenström macroglobulinemia is a rare, slow-growing lymphoproliferative disorder that is estimated to affect only 1,000 to 1,500 individuals each year in the… Continue reading →